Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DXS3FE
|
||||
Drug Name |
(Z)-(5-{6-[3-(4-Methoxyphenyl)-ureido]-2-oxo-1,2-dihydroindol-3-ylidene-methyl}-2,4-dimethyl-1H-pyrrol-3-yl)acetic acid
|
||||
Synonyms |
CHEMBL1173150
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C25H24N4O5
|
||||
Canonical SMILES |
COc1ccc(NC(=O)Nc2ccc3\\C(=C\\c4[nH]c(C)c(CC(=O)O)c4C)\\C(=O)Nc3c2)cc1
|
||||
InChI |
InChI=1S/C25H24N4O5/c1-13-19(12-23(30)31)14(2)26-21(13)11-20-18-9-6-16(10-22(18)29-24(20)32)28-25(33)27-15-4-7-17(34-3)8-5-15/h4-11,26H,12H2,1-3H3,(H,29,32)(H,30,31)(H2,27,28,33)/b20-11-
|
||||
InChIKey |
FUNGTOAZDDISQB-JAIQZWGSSA-N
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
FL cytokine receptor | Target Info | [1587926] | |||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04060:Cytokine-cytokine receptor interaction | |||||
Hematopoietic cell lineage | |||||
Pathways in cancer | |||||
Transcriptional misregulation in cancer | |||||
Acute myeloid leukemia | |||||
Central carbon metabolism in cancer | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.